Quarterly Result9 Feb 2026, 01:52 pm
Zydus Lifesciences Announces Q3 & 9M FY26 Financial Results: Revenue Up 30% and 17% Respectively
AI Summary
Zydus Lifesciences Ltd. announced its unaudited consolidated financial results for the quarter and nine months ended December 31, 2025. The company reported a 30% YoY increase in revenue from operations for Q3 FY26, amounting to Rs. 68,645 mn. For 9M FY26, the revenue from operations stood at Rs. 195,614 mn, up 17% over the previous year. The EBITDA for Q3 FY26 was Rs. 18,164 mn, up 31% YoY, with an EBITDA margin of 26.5%. The net profit (adjusted) for the quarter was Rs. 11,109 mn, up 9% YoY. The net debt to equity ratio as on 31st December 2025 was 0.11x, while the net debt to EBITDA stood at 0.36x at the end of December 2025.
Key Highlights
- Revenue from operations for Q3 FY26 up 30% to Rs. 68,645 mn
- EBITDA for Q3 FY26 up 31% YoY to Rs. 18,164 mn
- EBITDA margin for Q3 FY26 at 26.5%, an improvement of 20 bps YoY
- Net profit (adjusted) for Q3 FY26 up 9% YoY to Rs. 11,109 mn
- Revenue from operations for 9M FY26 up 17% to Rs. 195,614 mn